{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:37:17Z","timestamp":1781199437984,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13318-023-00868-y","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:02:10Z","timestamp":1700902930000},"page":"43-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration\u2013Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2281-2655","authenticated-orcid":false,"given":"Deema Hilmi","family":"Adawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Ben","family":"Fredj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-barghouthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichrack","family":"Dridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Lubada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Manasra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Aouam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"issue":"8","key":"868_CR1","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et\u00a0al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022\u20138.","journal-title":"Blood"},{"key":"868_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.5581\/1516-8484.20110081","volume":"33","author":"DH Martins","year":"2011","unstructured":"Martins DH, Wagner SC, Dos Santos TV, et\u00a0al. Monitoring imatinib plasma concentrations in chronic myeloid leukemia. Rev Bras de Hematol Hemoter. 2011;33:302\u20136.","journal-title":"Rev Bras de Hematol Hemoter."},{"issue":"5\u20136","key":"868_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000324900","volume":"87","author":"N Takahashi","year":"2011","unstructured":"Takahashi N, Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology. 2011;87(5\u20136):241\u20138.","journal-title":"Pharmacology"},{"issue":"4","key":"868_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","volume":"53","author":"P le Coutre","year":"2004","unstructured":"le Coutre P, Kreuzer K-A, Pursche S, et\u00a0al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol. 2004;53(4):313\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 10","key":"868_CR5","doi-asserted-by":"publisher","first-page":"S1541","DOI":"10.21037\/tcr.2017.09.08","volume":"6","author":"DT Barratt","year":"2017","unstructured":"Barratt DT, Somogyi AA. Role of pharmacogenetics in personalised imatinib dosing. Trans Cancer Res. 2017;6(Suppl 10):S1541\u201357.","journal-title":"Trans Cancer Res."},{"issue":"3","key":"868_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/clpt.2013.92","volume":"94","author":"A Filppula","year":"2013","unstructured":"Filppula A, Tornio A, Niemi M, Neuvonen P, Backman J. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clinc Pharmacol Ther. 2013;94(3):383\u201393.","journal-title":"Clinc. Pharmacol. Ther."},{"key":"868_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-010-1142-7","volume":"90","author":"P Mlejnek","year":"2011","unstructured":"Mlejnek P, Dolezel P, Faber E, Kosztyu P. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells. Ann Hematol. 2011;90:837\u201342.","journal-title":"Ann Hematol"},{"issue":"2","key":"868_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/genes13020311","volume":"13","author":"B Franczyk","year":"2022","unstructured":"Franczyk B, Rysz J, Gluba-Brz\u00f3zka A. Pharmacogenetics of drugs used in the treatment of cancers. Genes. 2022;13(2):311.","journal-title":"Genes"},{"key":"868_CR9","unstructured":"Ratain MJ, Plunkett Jr W. Principles of pharmacokinetics. In: Holland-Frei Cancer Medicine, 6th ed; Kufe, DW, Pollock, RE, Weichselbaum, RR, Bast, RC, Jr, Gansler, TS, Holland, JF, Frei, E, III, eds. 2003."},{"key":"868_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"868_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D, et\u00a0al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22(5):935\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"868_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2009.24.1.1","volume":"24","author":"J-S Kang","year":"2009","unstructured":"Kang J-S, Lee M-H. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1.","journal-title":"Korean J Intern Med"},{"issue":"Suppl 10","key":"868_CR13","doi-asserted-by":"publisher","first-page":"S1500","DOI":"10.21037\/tcr.2017.10.30","volume":"6","author":"HY Kim","year":"2017","unstructured":"Kim HY, Martin JH, Mclachlan AJ, Boddy AV. Precision dosing of targeted anticancer drugs\u2014challenges in the real world. Transl Cancer Res. 2017;6(Suppl 10):S1500\u201311.","journal-title":"Transl Cancer Res."},{"key":"868_CR14","unstructured":"Adawi D, Dridi I, Lubada M, et\u00a0al. Development and clinical validation of an HPLC-PDA method of imatinib mesylate in human plasma: interest in therapeutic drug monitoring. J Pharm\u00a0Drug\u00a0Deliv Res. 2023;12(4)."},{"key":"868_CR15","unstructured":"ICH M10 on bioanalytical method validation\u2014Scientific guideline. European Medicines Agency: Amsterdam, the Netherlands. 2019."},{"issue":"4","key":"868_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503\u201312.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"868_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/FTD.0b013e31829b88f5","volume":"35","author":"T Pawinski","year":"2013","unstructured":"Pawinski T, Luszczynska P, Durlik M, et\u00a0al. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. Ther Drug Mon. 2013;35(6):760\u20139.","journal-title":"Ther Drug Mon"},{"issue":"8476","key":"868_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"327","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet. 1986;327(8476):307\u201310.","journal-title":"The lancet"},{"issue":"8","key":"868_CR19","first-page":"525","volume":"33","author":"JS Krouwer","year":"1995","unstructured":"Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem. 1995;33(8):525\u20138.","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"9","key":"868_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23374","volume":"34","author":"M Ammar","year":"2020","unstructured":"Ammar M, Louati N, Frikha I, et\u00a0al. Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients. J Clin Lab Anal. 2020;34(9): e23374.","journal-title":"J Clin Lab Anal"},{"key":"868_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5581\/1516-8484.20130030","volume":"35","author":"VM Rezende","year":"2013","unstructured":"Rezende VM, Rivellis AJ, Gomes MM, et\u00a0al. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. Rev Bras Hematol Hemoter. 2013;35:103\u20138.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"5","key":"868_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1248\/bpb.b15-00103","volume":"38","author":"M Miura","year":"2015","unstructured":"Miura M. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull. 2015;38(5):645\u201354.","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"868_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3390\/ph14020162","volume":"14","author":"F Le Louedec","year":"2021","unstructured":"Le Louedec F, Gallais F, Thomas F, et\u00a0al. Limited sampling strategy for determination of ibrutinib plasma exposure: joint analyses with metabolite data. Pharmaceuticals. 2021;14(2):162.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"868_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","volume":"33","author":"AF van der Meer","year":"2011","unstructured":"van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C. Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit. 2011;33(2):133\u201346.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"868_CR25","doi-asserted-by":"crossref","first-page":"e00384","DOI":"10.1128\/AAC.00384-19","volume":"63","author":"SH van den Elsen","year":"2019","unstructured":"van den Elsen SH, Sturkenboom MG, Akkerman OW, et\u00a0al. Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients. Antimicrob Agents Chemother. 2019;63(7):e00384-e419.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"868_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","volume":"37","author":"M von Mehren","year":"2011","unstructured":"von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev. 2011;37(4):291\u20139.","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"868_CR27","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/jcph.953","volume":"57","author":"BA Adeagbo","year":"2017","unstructured":"Adeagbo BA, Olugbade TA, Durosinmi MA, et\u00a0al. Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance. J Clin Pharmacol. 2017;57(12):1554\u201363.","journal-title":"J Clin Pharmacol"},{"issue":"14","key":"868_CR28","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et\u00a0al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"868_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd L, Csajka C, et\u00a0al. Population pharmacokinetics of imatinib and the role of \u03b11-acid glycoprotein. Br J Clin Pharmacol. 2006;62(1):97\u2013112.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"868_CR30","first-page":"P59-P","volume":"75","author":"Y Zhu","year":"2004","unstructured":"Zhu Y, Statkevich P, Curtis D, et\u00a0al. Effects of age and gender on the pharmacokinetics of lonafarnib (L) following a single oral dose. Clin Pharmacol Ther. 2004;75(2):P59-P.","journal-title":"Clin Pharmacol Ther."},{"issue":"10","key":"868_CR31","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.clinthera.2009.10.009","volume":"31","author":"S Parrillo-Campiglia","year":"2009","unstructured":"Parrillo-Campiglia S, Ercoli MC, Umpierrez O, et\u00a0al. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther. 2009;31(10):2224\u201332.","journal-title":"Clin Ther"},{"issue":"suppl 10","key":"868_CR32","doi-asserted-by":"publisher","first-page":"S1558","DOI":"10.21037\/tcr.2017.09.09","volume":"6","author":"JA Touma","year":"2017","unstructured":"Touma JA, McLachlan AJ, Gross AS. The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology. Transl Cancer Res. 2017;6(suppl 10):S1558\u201391.","journal-title":"Transl Cancer Res."},{"issue":"4","key":"868_CR33","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1111\/bcp.15084","volume":"88","author":"J Adiwidjaja","year":"2022","unstructured":"Adiwidjaja J, Gross AS, Boddy AV, McLachlan AJ. Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens. Br J Clin Pharmacol. 2022;88(4):1735\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"868_CR34","first-page":"26","volume":"1","author":"M Ansari","year":"2016","unstructured":"Ansari M, Kalantary-Khandani B, Pardakhty A, Safavi M, Mosavi N, Mohajeri E. Population pharmacokinetics of imatinib and its application to the therapeutic drug monitoring: Middle East CML population. Gulf J Oncolog. 2016;1(22):26\u201336.","journal-title":"Gulf J Oncolog."},{"issue":"8","key":"868_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4357","volume":"9","author":"R Nakahara","year":"2021","unstructured":"Nakahara R, Sumimoto T, Tanaka R, Ogata M, Itoh H. Successful determination of imatinib re-administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction. Clin Case Rep. 2021;9(8): e04357.","journal-title":"Clin Case Rep."},{"issue":"2","key":"868_CR36","first-page":"61","volume":"12","author":"H Khurana","year":"2021","unstructured":"Khurana H, Kumar A, Khurana A, Abhisheka K, Jha VK. Therapeutic drug monitoring of imatinib in patients of chronic myeloid leukemia-chronic phase. J Pharmacol Pharmacother. 2021;12(2):61\u20137.","journal-title":"J Pharmacol Pharmacother"},{"issue":"2","key":"868_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, et\u00a0al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101(2):473\u20135.","journal-title":"Blood"},{"issue":"8","key":"868_CR38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/aps.2010.79","volume":"31","author":"QB Li","year":"2010","unstructured":"Li QB, Chen C, Chen ZC, et\u00a0al. Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacol Sin. 2010;31(8):999\u20131004.","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"868_CR39","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et\u00a0al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109(8):3496\u20139.","journal-title":"Blood"},{"issue":"12","key":"868_CR40","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G, Koller D, Zubiaur P, Abad-Santos F. Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther. 2019;41(12):2558-70.e7.","journal-title":"Clin Ther."},{"issue":"14","key":"868_CR41","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, et\u00a0al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381.","journal-title":"J Clin Oncol"},{"issue":"2","key":"868_CR42","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3892\/ol.2016.4780","volume":"12","author":"P Herviou","year":"2016","unstructured":"Herviou P, Thivat E, Richard D, et\u00a0al. Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol Lett. 2016;12(2):1223\u201332.","journal-title":"Oncol Lett"},{"key":"868_CR43","first-page":"174","volume":"35","author":"SR Dos Reis","year":"2013","unstructured":"Dos Reis SR, Quixad\u00e1 AT, Nunes ST, et\u00a0al. Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Rev Bras Hematol Hemoter. 2013;35:174\u20139.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"2","key":"868_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13318-019-00598-0","volume":"45","author":"JQ Gu","year":"2020","unstructured":"Gu JQ, Guo YP, Jiao Z, Ding JJ, Li GF. How to handle delayed or missed doses: a population pharmacokinetic perspective. Eur J Drug Metab Pharmacokinet. 2020;45(2):163\u201372.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"14","key":"868_CR45","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.patrec.2008.06.018","volume":"29","author":"A Isaksson","year":"2008","unstructured":"Isaksson A, Wallman M, G\u00f6ransson H, Gustafsson MG. Cross-validation and bootstrapping are unreliable in small sample classification. Pattern Recognit Lett. 2008;29(14):1960\u20135.","journal-title":"Pattern Recognit Lett"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00868-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-023-00868-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-023-00868-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T19:09:01Z","timestamp":1704913741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-023-00868-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1007\/s13318-023-00868-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"5 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.A. was responsible for conceiving and designing the study, collecting the blood samples, performing data analysis, interpreting the data, and writing the manuscript; N.B. for critically revising the manuscript and contributing in writing the manuscript; A.A. for contributing in samples analysis HPLC method validation; I.D. for contributing in HPLC method validation and development for imatinib detection; M.L. for contributing in sample analysis and in HPLC method validation; M.M. for facilitating cooperation for patients hospital admission and following up patients; and K.A. for providing critical intellectual input, revising the manuscript, and contributing in writing the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data and materials used in this study are available upon reasonable request. Researchers interested in accessing the data and materials may contact Deema hilmi adawi at deema.hilmi.adawi@gmail.com.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All procedures in this study were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. The study was approved by the Palestinian ministry of Health on 15 September 2021","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all study participants. They were informed about the nature of the study, its objectives, and the use of their data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}